

Supplemental file S2 bis: Total number of patients to be included in post-marketing studies for each drug

<b>Drug</b>	<b>Total number of patients to be included in post-marketing studies</b>	<b>Percentage of industry funders</b>	<b>Percentage of non-industry funders</b>
Varenicline	1045002	90.8	9.2
Saxagliptin	785853	99.6	0.4
Exenatide	420256	99.3	0.7
Dabigatran	368063	93.1	6.9
Abatacept	240227	99.6	0.4
Prasugrel	128744	66.9	33.1
Sitagliptin	113824	91.8	8.2
Ranibizumab	89765	81.9	18.1
Aliskiren	76864	96.6	3.4
Sorafenib	76434	66.2	33.8
Liraglutide	73106	92.0	8.0
Lenalidomide	60805	62.8	37.2
Lapatinib	45881	77.4	22.6
Paliperidone	43024	92.6	7.4
Micafungin	41363	95.0	5.0
Entecavir	39787	65.5	34.5
Darunavir	39773	94.7	5.3
Certolizumab pegol	37523	91.6	8.4
Sunitinib	37320	70.7	29.3
Tocilizumab	36262	91.8	8.2
Denosumab	32688	90.2	9.8
Raltegravir	31285	60.8	39.2
Lacosamide	30236	93.9	6.1
Fesoterodine fumarate	23699	97.2	2.8
Panitumumab	22585	66.9	33.1
Methoxy polyethylene	22102	99.2	0.8
Ustekinumab	20873	95.5	4.5
Pazopanib	19332	54.1	45.9
Tigecycline	19322	89.3	10.7
Dasatinib	19320	72.2	27.8
Golimumab	18801	90.1	9.9
Silodosin	17591	97.5	2.5
Febuxostat	16330	88.8	11.2
Nilotinib	15657	77.0	23.0
Canakinumab	15418	98.2	1.8
Telbivudine	13590	55.6	44.4
Tolvaptan	13552	89.7	10.3
Plerixafor	13450	84.6	15.4
Ambrisentan	12300	46.1	53.9

<b>Drug</b>	<b>Total number of patients to be included in post-marketing studies</b>	<b>Percentage of industry funders</b>	<b>Percentage of non-industry funders</b>
Rotigotine	12258	96.8	3.2
Maraviroc	11957	74.3	25.7
Dronedarone	10947	62.7	37.3
Degarelix	10811	93.0	7.0
Ranolazine	10614	69.8	30.2
Deferasirox	8812	86.4	13.6
Ofatumumab	7988	84.0	16.0
Nepafenac	7627	86.2	13.8
Sapropterin	6328	90.3	9.7
Eculizumab	6065	95.5	4.5
Eltrombopag	5590	85.2	14.8
Mecasermin	5291	88.5	11.5
Ulipristal	4932	90.9	9.1
Etravirine	4881	46.4	53.6
Retapamulin	4819	95.6	4.4
Posaconazole	4391	65.1	34.9
Collagenase clostridium	3897	91.2	8.8
Anidulafungin	3819	70.8	29.2
Methylnaltrexone bromide	3581	96.6	3.4
Doripenem	3204	87.3	12.7
Nelarabine	3104	15.6	84.4
Rilonacept	2790	84.1	15.9
Asenapine maleate	2179	100.0	0.0
Romiplostim	1627	95.1	4.9
Tipranavir	1401	98.9	1.1
Rufinamide	1174	76.3	23.7
Alglucidase	803	61.4	38.6
Idursulfase	408	80.4	19.6
Galsulfase	269	100.0	0.0
Velaglucerase alfa	67	100.0	0.0

Supplemental file S3 bis: Population in preapproval pivotal trials and post-marketing studies

Drug	Population in preapproval pivotal trials	Population in post-marketing studies			
		Another indication	Originally-approved indication	Both in originally approved indication and in other(s) indication	Total
Dabigatran	18040	10896	332151	25016	368063
Prasugrel	13457	1960	126669	115	128744
Denosumab	7808	15825	16863	0	32688
Aliskiren	5663	20625	56239	0	76864
Dronedarone	4604	20	10927	0	10947
Varenicline	4198	1847	1024229	18926	1045002
Tocilizumab	4190	2201	34061	0	36262
Saxagliptin	4148	396	785457	0	785853
Febuxostat	4101	854	15476	0	16330
Liraglutide	3978	9509	62587	1010	73106
Ulipristal	3754	4012	920	0	4932
Tigecycline	2758	1339	6291	11692	19322
Methoxy polyethylene	2398	8	22094	0	22102
Golimumab	2297	1222	17579	0	18801
Asenapine maleate	2294	0	2179	0	2179
Sitagliptin	2220	2794	110745	285	113824
Doripenem	2117	267	2937	0	3204
Ustekinumab	1996	3793	17080	0	20873
Fesoterodine fumarate	1935	182	23517	0	23699
Entecavir	1814	0	39787	0	39787
Paliperidone	1665	2548	35755	4721	43024
Micafungin	1643	1105	39983	275	41363
Ranolazine	1593	2945	5773	1896	10614
Exenatide	1446	2810	417301	145	420256
Abatacept	1382	5622	234605	0	240227
Telbivudine	1367	0	13590	0	13590
Lacosamide	1308	1133	29103	0	30236
Etravirine	1203	0	4881	0	4881
Posaconazole	1202	1949	1282	1160	4391
Rotigotine	1163	4067	7671	520	12258
Tipranavir	1159	0	1365	36	1401
Ranibizumab	1139	20541	36906	32318	89765
Rufinamide	1097	288	886	0	1174
Certolizumab pegol	1088	1200	33077	3246	37523
Sildenafil	923	1339	16252	0	17591
Anidulafungin	857	792	2993	34	3819
Sorafenib	769	54317	18809	3308	76434
Raltegravir	699	83	31202	0	31285
Nepafenac	688	815	6812	0	7627
Darunavir	637	0	39773	0	39773

Drug	Population in preapproval pivotal trials	Population in post-marketing studies			
		Another indication	Originally-approved indication	Both in originally approved indication and in other(s) indication	Total
Plerixafor	623	1467	11644	339	13450
Degarelix	610	791	10020	0	10811
Deferasirox	586	153	8609	50	8812
Dasatinib	565	9267	9090	963	19320
Sunitinib	481	16462	18362	2496	37320
Panitumumab	461	5197	16874	514	22585
Maraviroc	448	560	11397	0	11957
Pazopanib	435	10363	8060	909	19332
Tolvaptan	418	12221	356	975	13552
Ambrisentan	393	715	11585	0	12300
Collagenase clostridium	374	3897	0	0	3897
Lapatinib	324	7678	37714	489	45881
Methylnaltrexone bromide	321	1359	2222	0	3581
Eltrombopag	232	2957	2533	100	5590
Retapamulin	210	267	4417	135	4819
Nilotinib	196	2431	8531	4695	15657
Lenalidomide	193	19105	39873	1827	60805
Nelarabine	190	35	3069	0	3104
Ofatumumab	154	3076	2595	2317	7988
Romiplostim	125	543	1084	0	1627
Idursulfase	96	0	408	0	408
Sapropterin	88	1133	5195	0	6328
Eculizumab	87	3861	2204	0	6065
Mecasermin	70	623	4668	0	5291
Riloncept	47	2765	25	0	2790
Galsulfase	39	0	269	0	269
Canakinumab	31	15157	261	0	15418
Velaglucerase alfa	25	0	67	0	67
Alglucidase	18	0	803	0	803

Supplemental file S6 bis: Location of post-marketing studies (sample size by location)

	Location						
	North America	Europa	Others	North America + Europa	North America + Others	Europa + Others	North America + Europa + Others
Abatacept	2267	2801	1575	1255	1715	0	9390
Alglucidase	633	5	0	83	22	20	40
Aliskiren	8269	3870	5760	5467	975	3097	33667
Ambrisentan	2128	6116	196	64	524	0	2330
Anidulafungin	1115	225	214	0	282	21	776
Asenapine maleate	950	0	0	0	0		0
Canakinumab	164	320	34	1037	0	274	13569
Certolizumab pegol	7278	5383	2401	3225	271	0	6265
Collagenase clostridium	1402	541	79	0	1286	0	400
Dabigatran	272415	47930	9639	636	0	7096	21220
Darunavir	755	2880	4076	12	1213	576	2940
Dasatinib	7476	2941	1139	768	195	484	5866
Deferasirox	1473	1023	1148	0	0	2506	2575
Degarelix	1613	5646	1522	783	0	0	1147
Denosumab	1168	4547	2692	427	0	1439	16134
Doripenem	82	195	818	52	0	0	1911
Dronedarone	480	4143	279	0	0	556	5436
Eculizumab	4683	447	52	60	92	80	463
Eltrombopag	1486	458	992	82	0	100	1059
Entecavir	807	1096	21848	4	200	184	14460
Etravirine	857	1730	570	30	671	279	536
Exenatide	371779	5876	10283	736	3323	2963	25151
Febuxostat	5473	0	1424	0	7500	0	744
Fesoterodine fumarate	4555	1231	2245	0	0	794	8210

	Location						
	North America	Europa	Others	North America + Europa	North America + Others	Europa + Others	North America + Europa + Others
Galsulfase	10	0	0	0	200	0	59
Golimumab	5459	5031	1361	706	11	120	811
Idursulfase	0	0	81	79	0	108	118
Lacosamide	1597	4167	946	1210	0	0	3281
Lapatinib	5446	9359	2989	502	1106	876	22398
Lenalidomide	22422	19825	1874	1804	1916	1972	8846
Liraglutide	15787	12960	13865	717	0	415	26892
Maraviroc	1268	1849	561	129	876	186	5698
Mecasermin	2073	3198	0	0	0	0	0
Methoxy polyethylene	340	13375	4841	0	0	2828	718
Methylnaltrexone bromide	1968	31	0	0	0	0	1462
Micafungin	37521	664	1518	0	84	619	836
Nelarabine	95	720	13	0	36	40	1900
Nepafenac	5927	227	1021	0	0	0	0
Nilotinib	1660	4393	1964	175	512	218	2882
Ofatumumab	2401	1549	20	60	14	122	3294
Paliperidone	4400	1064	10125	0	838	4753	11816
Panitumumab	2888	8858	164	375	0	0	1700
Pazopanib	5947	5436	2684	374	207	102	4518
Plerixafor	2374	850	164	0	61	46	0
Posaconazole	154	1370	126	96	0	0	600
Prasugrel	23597	42550	7015	4760	17372	0	26550
Raltegravir	3106	4949	8048	366	3156	1173	4308
Ranibizumab	17679	20576	9883	694	232	3832	33851
Ranolazine	4524	551	310	0	0	0	5102

	Location						
	North America	Europa	Others	North America + Europa	North America + Others	Europa + Others	North America + Europa + Others
Retapamulin	784	0	3000	0	508	465	60
Rilonacept	1242	30	0	0	0	244	1274
Romiplostim	280	119	76	63	62	0	175
Rotigotine	2229	3696	2553	220	601	2197	371
Rufinamide	230	278	366	75	0	0	0
Sapropterin	5120	1018	0	0	190	0	0
Saxagliptin	166072	594	13757	0	501	2670	21205
Silodosin	885	1196	1559	0	0	0	0
Sitagliptin	5577	2079	12049	164	804	3770	21728
Sorafenib	17405	13223	17312	973	2681	3230	20954
Sunitinib	8448	7676	2806	2557	2006	167	10074
Telbivudine	159	132	8934	0	308	367	1790
Tigecycline	473	1987	9632	0	1175	473	1588
Tipranavir	71	504	0	0	246	0	84
Tocilizumab	2511	17868	4033	1054	228	1270	9070
Tolvaptan	1227	304	3131	0	1300	0	4500
Ulipristal	855	2845	51	579	60	542	0
Ustekinumab	2823	2649	2004	166	0	1290	9859
Varenicline	34574	67592	6523	1307	360	0	18706
Velaglucerase alfa	0	50	17	0	0	0	0